Search Results for drug prices

Showing 1 – 17

Updated: Pharma Profits Continue to Dwarf R&D Spending as Pressure Mounts By Zachary Brennan - Published 27 March 2017

With the repeal of Obamacare on life support, the furor over rising prescription drug prices and President Donald Trump’s support for the cause could end up filling the vacant crossroads where bipartisanship meets change.

Categories: News, US, Business Skills, Drugs, Government affairs

Tags: drug company profits, drug prices, R&D spending on pharmaceuticals

Bills Introduced in March: Importation, Cancer Drugs and PBM Transparency By Zachary Brennan - Published 17 March 2017

At least nine US House and Senate bills introduced in March would impact the pharmaceutical industry, including three to allow for more prescription drug imports from Canada, pharmacy benefit management (PBM) transparency and one on cost sharing for cancer medicines.

Categories: News, US, FDA, Biologics and biotechnology, Drugs, Government affairs

Tags: Cummings, Sanders, drug prices, PBMs

Trump Working on ‘New System’ to Increase Drug Competition By Zachary Brennan - Published 07 March 2017

President Donald Trump tweeted Tuesday morning that he’s “working on a new system where there will be competition in the Drug Industry,” though how such a system would work alongside the generic drug and biosimilar competitors, remains to be understood.

Categories: News, US, FDA, Drugs, Government affairs

Tags: Trump, drug prices, Cummings, Sanders, FDA regulations

Senators Call on HHS to Allow Canadian Drug Imports if Prices Spike By Zachary Brennan - Published 14 February 2017

Sens. Charles Grassley (R-IA), John McCain (R-AZ) and Amy Klobuchar (D-MN) on Tuesday sent a letter to Tom Price, the newly confirmed secretary of the Department of Health and Human Services (HHS), calling on him to fast-track the approval of prescription drugs imported from Canada in four different circumstances, including if the price of a drug increases significantly.

Categories: News, US, FDA, Crisis management, Drugs, Government affairs

Tags: Klobuchar, McCain, Grassley, Canada drug imports, drug prices

Senate Democrats to Trump: Work With us to Lower Drug Prices By Zachary Brennan - Published 20 December 2016

Sens. Sherrod Brown (D-OH), Al Franken (D-MN) and 17 of their Democratic and Independent colleagues on Tuesday sent a letter to President-elect Donald Trump, urging him to combat the pharmaceutical industry’s “abusive tactics” that “price lifesaving drugs out of reach for those in need.”

Categories: News, US, Drugs, Reimbursement

Tags: Franken, Elizabeth Warren, Trump, CMS, drug prices

Vermont Drug Price Transparency: New Law Calls Out Egregious Price Spikes By Zachary Brennan - Published 06 December 2016

Last June, Vermont Governor Peter Shumlin (D) signed into law a new pharmaceutical price transparency bill that sought to expose the companies and products seeing the largest price hikes.

Categories: News, US, Biologics and biotechnology, Business and Leadership, Drugs, Regulatory intelligence, Regulatory strategy, Reimbursement, Submission and registration

Tags: pharmaceutical price transparency, drug prices, increases in drug prices, Vermont pharmaceuticals, Medicaid

Generic Drug Backlog at FDA: A Dive Into the Confusing Numbers By Zachary Brennan - Published 01 November 2016

As the debate over skyrocketing drug prices continues, at least one solution has cropped up in nearly every conversation: Reduce the generic drug backlog at the US Food and Drug Administration (FDA), create more competition and drug prices will come down.

Categories: News, US, FDA, Generic drugs, Government affairs

Tags: generic drug approvals, drug prices, high drug prices, ANDA approvals, generic drug backlog, FDA backlog

New House, Senate Bills Would Require Companies to Justify Drug Price Hikes of More Than 10% By Zachary Brennan - Published 15 September 2016

US Sens. Tammy Baldwin (D-WI) and John McCain (R-AZ), as well as Rep. Jan Schakowsky (D-IL), on Thursday introduced new bills that would require drug manufacturers to disclose and provide more information about planned drug price increases, as well as data on research and development costs.

Categories: News, US, FDA, Drugs, Government affairs

Tags: drug prices, Schakosky, Tammy Baldwin, John McCain, drug price transparency

What Drugs Really Cost: GAO Wants CMS to Find Out By Zachary Brennan - Published 02 August 2016

In order to help ensure the accuracy of Medicare Part B drug payment rates, the US Government Accountability Office (GAO) on Monday urged Congress to require all manufacturers of Part B drugs paid at average sales price (ASP) to submit sales price data to the Centers for Medicare & Medicaid Services (CMS). 

Categories: News, US, Biologics and biotechnology, Drugs, Government affairs, Reimbursement

Tags: GAO, CMS drug prices, Part B, drug pricing, ASP

Asia Regulatory Roundup: China’s Anti-Corruption Agency Chides CFDA Over Loopholes (7 June 2016) By Nick Paul Taylor - Published 07 June 2016

Welcome to our Asia Regulatory Roundup, our weekly overview of the top regulatory news in Asia.

Categories: News, Asia, CDSCO, CFDA, Biologics and biotechnology, Clinical, Crisis management, Drugs, Regulatory intelligence, Regulatory strategy

Tags: Asia Regulatory Roundup, China drug regulations, DCGI, Pakistan drug prices

European Regulators Drawn Into Debate on Drug Pricing By Zachary Brennan - Published 12 May 2016

Although drug regulators aren’t supposed to be concerned with pricing when making decisions on products’ safety and efficacy, they’re increasingly being drawn into what two representatives of the European Medicines Agency (EMA) and the heads of two national regulators call an “acrimonious debate” over drug costs.

Categories: News, Europe, US, EC, EMA, MHRA, NICE, Biologics and biotechnology, Crisis management, Drugs, Government affairs

Tags: EU drug prices, pharmaceutical drug pricing, drug price policies, EMA and drug pricing

MSF: Access to New TB Medicines Falters Despite Conditional Approvals By Zachary Brennan - Published 21 March 2016

Doctors without Borders (MSF) released a new report on Monday offering details on how the first new drugs in nearly half a century were conditionally approved to treat tuberculosis (TB),  though only 2% of the roughly 150,000 who could benefit from these treatments have access to them.

Categories: News, Africa, Asia, Latin America and Caribbean, EMA, WHO, Crisis management, Drugs, Government affairs, Regulatory intelligence, Submission and registration

Tags: MSF, Doctors Without Borders, TB medicines, TB drug prices, Otsuka

Asia Regulatory Roundup: CFDA Consults on Good Supply Practices, Traceability (23 February 2016) By Nick Paul Taylor - Published 23 February 2016

Welcome to our Asia Regulatory Roundup, our weekly overview of the top regulatory news in Asia.

Categories: News, Asia, CDSCO, CFDA, WHO, Compliance, Crisis management, Drugs, Due Diligence, Manufacturing, Quality, Regulatory intelligence, Regulatory strategy

Tags: Asia Regulatory Roundup, Ali Health, drug monitoring, drug prices, traditional medicine

Senators Urge Obama to Take Action on Drug Prices By Zachary Brennan - Published 03 February 2016

Policy solutions to bring down the rising tide of prescription drug prices should be included in next year’s budget, eight senators said in a letter sent to President Barack Obama on Tuesday.

Categories: News, US, Crisis management, Drugs, Government affairs, Postmarket surveillance, Reimbursement

Tags: drug prices, Medicare Part D, government drug price negotiations, Obama budget FY2017

Senate Committee Considers Priority Reviews to Stem the Tide of Off-Patent Drug Price Hikes By Zachary Brennan - Published 09 December 2015

Sens. Susan Collins (R-Maine) and Claire McCaskill (D-Mo.) hosted a hearing Wednesday to discuss steep price increases for off-patent drugs and what can be done to ensure patients and hospitals can afford these drugs moving forward.

Categories: News, US, FDA, FTC, Crisis management, Drugs, Ethics, Government affairs, Manufacturing, Reimbursement

Tags: drug pricing, Martin Shkreli, Turing, Daraprim, off patent drug prices, Senate committee

Senators Call on FDA to Allow Certain Canadian Drug Imports By Zachary Brennan - Published 23 November 2015

The US Food and Drug Administration (FDA) should allow the importation of pharmaceutical products from Canada if they meet certain stipulations, Sens. Chuck Grassley (R-IA) and John McCain (R-AZ) wrote in a letter to Health and Human Services (HHS) Secretary Sylvia Burwell.

Categories: News, US, FDA, Government affairs, Manufacturing, Postmarket surveillance, Product withdrawl and retirement, Quality, Reimbursement

Tags: drug prices, McCain, Grassley, Canadian imports, pharmaceutical imports

Senators Investigate Rising Drug Prices as HHS Plans Action By Zachary Brennan - Published 04 November 2015

The fire stoked by rising drug prices is starting to spread through government, particularly as Sens. Susan Collins (R-ME) and Claire McCaskill (D-MO) on Wednesday announced a bipartisan Senate investigation into pharmaceutical price gouging with letters to four companies.

Categories: News, US, DOJ, FDA, FTC, Business Skills, Compliance, Drugs, Government affairs, Regulatory intelligence, Regulatory strategy

Tags: Elijah Cummings, Valeant Pharmaceuticals, drug prices, Senate investigation